## Pathophysiology and Molecular Biology Non-Hodgkin Lymphoma (NHL) represents a heterogeneous group of lymphoproliferative malignancies arising from B-cell, T-cell, or natural killer (NK) cell lineages. Code C85.90 is utilized in clinical coding when a patient is diagnosed with NHL, but the specific histological subtype remains unspecified or is not documented, and the primary site of involvement is not clearly identified or is specified as 'unspecified.' The pathophysiology involves the clonal expansion of malignant lymphocytes at various stages of differentiation. These cells typically bypass normal regulatory mechanisms of the cell cycle and apoptosis. Genetic alterations, including chromosomal translocations (such as those involving the MYC, BCL2, or BCL6 genes), deletions, or point mutations, drive the oncogenic process. While C85.90 lacks histological specificity, the underlying process represents a systemic immune system dysregulation where malignant cells escape normal immune surveillance and infiltrate lymphoid or extranodal tissues. ## Clinical Presentation and B-Symptoms The clinical presentation of NHL is highly variable, depending on the subtype and site of involvement. The most common hallmark is painless peripheral lymphadenopathy, often involving the cervical, axillary, or inguinal lymph nodes. Patients may also present with constitutional 'B-symptoms,' which carry significant prognostic weight: unexplained weight loss exceeding 10% of body weight within six months, drenching night sweats, and persistent fevers higher than 38°C (100.4°F). Extranodal involvement occurs in approximately 25-30% of cases, potentially affecting the gastrointestinal tract, skin, central nervous system, or bone marrow. This may lead to site-specific symptoms such as abdominal pain, gastrointestinal bleeding, skin lesions, or cytopenias (anemia, neutropenia, or thrombocytopenia) due to marrow infiltration. ## Diagnostic Evaluation and Staging A definitive diagnosis of NHL requires an excisional lymph node biopsy or adequate core needle biopsies to allow for architectural assessment; fine-needle aspiration (FNA) is generally insufficient for a primary diagnosis. Histological examination, complemented by immunohistochemistry (IHC) and flow cytometry, is essential to determine the cell of origin (e.g., CD20 for B-cells). Staging is performed using the Lugano classification (derived from the Ann Arbor system), utilizing PET/CT imaging to assess the extent of nodal and extranodal disease. Bone marrow biopsy may be indicated if there is suspicion of marrow involvement not captured by imaging. Laboratory studies typically include a complete blood count (CBC), lactate dehydrogenase (LDH) levels—which serve as a marker of tumor burden—and comprehensive metabolic panels to assess renal and hepatic function. ## Management and Prognosis Treatment strategies are dictated by whether the lymphoma is classified as 'indolent' (slow-growing) or 'aggressive' (rapidly progressing). Indolent lymphomas may be managed with a 'watch and wait' approach or single-agent therapies, while aggressive lymphomas require immediate multi-agent chemotherapy. A common standard of care for B-cell NHL is the R-CHOP regimen (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone). Targeted therapies, such as CAR T-cell therapy and bispecific antibodies, have increasingly become part of the treatment landscape for relapsed or refractory cases. The International Prognostic Index (IPI) is used to predict clinical outcomes based on five risk factors: age, LDH, performance status, Ann Arbor stage, and number of extranodal sites. For cases coded as C85.90, clinicians must prioritize obtaining more specific pathology to refine the management plan.